Merck KGaA Cancer Drug Erbitux Seen Limited Threat To Roche Holding AG and Genentech, Inc. Avastin

LONDON, June 2 (Reuters) - Roche Holding AG shares jumped while Merck KGaA fell on Monday as investors decided rival drug Erbitux posed no immediate threat to Roche and Genentech Inc's cancer blockbuster Avastin.

Back to news